African genetic diversity

Yemaachi News

February 14, 2023

Liquid Biopsy – The necessary first step towards democratising precision oncology?African biotech holds the key to transforming not just the health of African people, but our economies as well

As one of Ghana's only labs equipped for molecular analysis, Bediako's team have tasked themselves with collecting data they believe will advance the development of medicine for cancer patients throughout the continent and diaspora
November 29, 2022

African biotech holds the key to transforming not just the health of African people, but our economies as well

As one of Ghana's only labs equipped for molecular analysis, Bediako's team have tasked themselves with collecting data they believe will advance the development of medicine for cancer patients throughout the continent and diaspora
May 25, 2022

Ghana startup strives for greater African representation in cancer research

As one of Ghana's only labs equipped for molecular analysis, Bediako's team have tasked themselves with collecting data they believe will advance the development of medicine for cancer patients throughout the continent and diaspora
March 21, 2022

Yemaachi, Africa’s Cancer Research Company, Raises Seed Round To Diversify Genomic Datasets & Advance Precision Oncology Globally

Yemaachi Biotech announced today the close of a $3 million seed round to advance its mission of diversifying precision oncology globally. V8 Capital led the round, with LifeLine Family Heritage Fund, Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital and Ethan Perlstein also participating.
November 3, 2021

Yemaachi Biotech, Lucence Aim to Improve Genomic Breast Cancer Testing in Ghana and Beyond

GenomeWeb covers Yemaachi's collaboration with cancer liquid biopsy firm Lucence to document and characterize the genomics of breast cancer in women of African descent.
May 30, 2021

H3D Partners with Yemaachi to Utilise African Genetic Diversity to Develop New Tools for Improving Treatment Outcomes for the African Patient Populations

The Holistic Drug Discovery and Development (H3D) Centre at the University of Cape Town (UCT) has entered into a strategic partnership with Yemaachi Biotech, to exploit African genetic diversity by identifying new therapies and platforms that optimize cancer treatments for African patient populations.